{"id":"W2570141807","doi":"10.1016/j.jaad.2016.11.041","title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial","year":2017,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":860,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriasis; Adalimumab; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Internal medicine; Placebo; Adverse effect; Surgery; Gastroenterology; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002486383,0.0003342289,0.001935606,0.00009162314,0.0004498146,0.00002490504,0.0006401668,0.0001329511,0.000004008049],"category_scores_gemma":[0.00007143558,0.0001455686,0.0002029604,0.00008189104,0.001246857,0.0001460475,0.00008830458,0.0002222654,3.402888e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003629472,"about_ca_system_score_gemma":0.0001366968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002178074,"about_ca_topic_score_gemma":0.00005951143,"domain_scores_codex":[0.9977421,0.0005646701,0.0009986457,0.0002840608,0.0001267497,0.0002837456],"domain_scores_gemma":[0.9936567,0.001766226,0.00391202,0.0004032325,0.0002009968,0.00006080275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.972634,0.001182362,0.01001472,0.000006378549,0.005709521,0.000004644535,0.002347039,0.0001345847,0.003208132,0.00002864628,0.0001749747,0.004555034],"study_design_scores_gemma":[0.8288165,0.006865943,0.1283557,0.0001331889,0.00293741,0.0002766127,0.001292966,0.00007952117,0.03044214,0.00002382383,0.0005467685,0.0002294444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940549,0.0006818874,0.0000958278,0.001851106,0.0001778004,0.002245322,0.0008734141,0.000005028417,0.00001468985],"genre_scores_gemma":[0.9993049,0.000251166,0.0002043052,0.00007681593,0.00005541273,0.00003438115,0.00003526992,0.00001824831,0.0000195342],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1438175,"threshold_uncertainty_score":0.5936114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03413351889159199,"score_gpt":0.3233729633831536,"score_spread":0.2892394444915616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}